Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen <it>Plasmodium falciparum</it> FVO merozoite surface protein-1 (MSP1<sub>42</sub>) administered intramuscularly with adjuvant system AS01

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen <it>Plasmodium falciparum</it> FVO merozoite surface protein-1 (MSP1<sub>42</sub>) administered intramuscularly with adjuvant system AS01

<p>Abstract</p> <p>Background</p> <p>The development of an asexual blood stage vaccine against <it>Plasmodium falciparum</it> malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical...

Full description

Bibliographic Details
Main Authors: Otsyula Nekoye, Angov Evelina, Bergmann-Leitner Elke, Koech Margaret, Khan Farhat, Bennett Jason, Otieno Lucas, Cummings James, Andagalu Ben, Tosh Donna, Waitumbi John, Richie Nancy, Shi Meng, Miller Lori, Otieno Walter, Otieno Godfrey Allan, Ware Lisa, House Brent, Godeaux Olivier, Dubois Marie-Claude, Ogutu Bernhards, Ballou W Ripley, Soisson Lorraine, Diggs Carter, Cohen Joe, Polhemus Mark, Heppner D Gray, Ockenhouse Christian F, Spring Michele D
Format: Article
Language:English
Published: BMC 2013-01-01
Series:Malaria Journal
Subjects:
Malaria
Vaccine
Merozoite surface protein-1
<it>Plasmodium</it>
Online Access:http://www.malariajournal.com/content/12/1/29

Similar Items

Similar Items